watch
Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Sector: Biological Products Except Diagnostic Substances Region: PA, United States


: | Nasdaq: INO


Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. The company is advancing a growing clinical and preclinical stage product pipeline. Partners and collaborators include MedImmune, the Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute and U.S. Military HIV Research Program. For more information, visit www.inovio.com.

Investor Calendar

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Taking Immunotherapy to the Next Level

Inovio Pharmaceuticals, Inc. video

Taking Immunotherapy to the Next Level

Executives

J. Joseph Kim, Ph.D., President, Chief Executive Officer, Director
JOSEPH KIM became the CEO of Inovio Pharmaceuticals with the completion of the company’s merger with VGX Pharmaceuticals in June 2009. Dr. Kim co-founded VGX in December 2000 as a start-up based on technology licensed from the University of Pennsylvania and was VGX’s CEO. Previously, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck & Co. These products include FDA-approved vaccines for hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim has published over 70 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels.
Dr. Kim has a B.Sc. in Chemical Engineering and Economics from MIT, where he was a U.S. Senate Honors Scholar. He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.
Dr. Kim has recognized with numerous honors during his career:
2002: MIT's Technology Review, one of the world's Top 100 Young Innovators 2002: Philadelphia Business Journal, one of "40 under 40" dynamic professionals 2003 and 2006: Details Magazine, selected as one of "50 Most Influential Men" 2004: World Economic Forum, selection of Dr. Kim and VGX Pharmaceuticals as one of 30 Technology Pioneers 2005: Newsweek International, profiled in annual "Who's Next" issue as one of 10 leaders, scientists, and executives at the forefront of change and impact in the world 2006: Forum of Young Global Leaders, an affiliate of the World Economic Forum, named a Young Global Leader among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries.
Peter Kies, Chief Financial Officer
PETER KIES has been CFO of Inovio since June 2002. Over the previous 16 years, Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from IPO to profitability. He was previously Chief Financial Officer at Newgen Results Corporation and held positions at Cytel Corporation and Ernst & Young, LLP.
Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.
Mark L. Bagarazzi, Chief Medical Officer
MARK L. BAGARAZZI joined Inovio in January, 2010, from Merck & Co., where he was director of worldwide regulatory affairs for vaccines and biologics. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He also successfully led the regulatory process through to FDA approval of RotaTeq®, Merck’s vaccine against rotavirus. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi was an assistant professor of pediatrics at Drexel College of Medicine and is a guest lecturer on vaccines and immunotherapeutics at the University of Pennsylvania School of Medicine. Previously, he was a guest lecturer at Johns Hopkins University.
He holds several patents and has co-authored dozens of scientific papers, focused on the subject of DNA vaccines, that have been published in peer-reviewed medical journals. He holds a BS in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from the University of Medicine and Dentistry of New Jersey.
Niranjan Y. Sardesai, Ph.D., Chief Operation Officer
NIRANJAN Y. SARDESAI was appointed Chief Operating Officer of Inovio in January 2012. He served as the Company’s Senior Vice President of Research and Development following the June 2009 merger with VGX Pharmaceuticals, at which company he held the same position. Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw Research and Development and expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer. Dr. Sardesai received a Doctor of Philosophy degree in Chemistry from the California Institute of Technology and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He completed fellowships at Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents.

News & Analysis